EVOLITO
Evolito, a new company developing and manufacturing electric motors and power electronics for aerospace applications, launched publicly today as a privately-owned business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005519/en/
Evolito was spun out earlier this year by YASA (the world-leading pioneer of automotive axial-flux electric motors acquired by Mercedes-Benz in July 2021) to exclusively commercialise YASA’s next-generation electric motor technology and IP for the rapidly-growing aerospace market.
The business’s axial-flux motor technology has been proven in volume series production in the automotive industry and has even greater advantages in the aerospace market. As such, Evolito is uniquely positioned to drive forward the commercialisation and adoption of electric flight.
Evolito’s ultra high-performance, low-weight axial-flux motors and power electronics are smaller, lighter and more robust than any other competing technology, opening up a range of new opportunities for Electric Vertical Take-off and Landing (eVTOL), Fixed Wing and distributed electric propulsion applications such as Urban Air Mobility (UAM).
The unique segmented topology of the Evolito motor is inherently more robust than other electric motor approaches, making it ideally suited to the demands of the aerospace market where safety is paramount.
Cyrus Jilla, Partner and Board Director, Waypoint Capital said, “At Waypoint, one of our thematic interests is in energy transition and sustainability, including electrification. We look to invest in businesses with unique disruptive technology led by outstanding teams. Evolito is a perfect fit for us and we look forward to backing the team as they develop their game-changing electrification solutions for the aerospace market, making emissions-free flight a reality.”
Alexis Zervoglos, Senior Partner, OSE said, “The electrification of flight is one of the most exciting market opportunities of our time. Realising this potential will require innovative new technology and an ability to scale to meet the fast-emerging demand. OSE is delighted to be supporting Evolito on its mission to accelerate the adoption of electric flight.”
Gareth Morris, Managing Director, Evolito said, “Electrification in aerospace is some ten years behind that of the automotive industry, but the market potential is huge. Electric Vertical Take-off and Landing, Electric Helicopter, Fixed-Wing and Urban Air Mobility aircraft need high power density, low weight electric powertrains with inherently high safety factors - a combination of attributes that are unique to our axial-flux electric motor and power electronics. By leveraging YASA’s unique IP in the aerospace market, Evolito will fast-track the commercialisation of electric flight and transform mobility as we know it.”
EDITOR’S NOTES
Electric drive solutions for the Urban Air Mobility market are forecast to grow to USD $90 billion and 160,000 vehicles by 2050. Source: Roland Berger “The high-flying industry: Urban Air Mobility takes off” , Nov, 2020.
Evolito http://www.evolito.co.uk/
Evolito is making all-electric flight a commercial reality with world-leading direct-drive electric propulsion solutions. Spun out of YASA in 2021, Evolito leverages technology proven by OEMs in the EV industry. Evolito’s axial-flux electric motors and power electronics offer the highest power and torque densities in class – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications – and is inherently more robust than competing technologies. The privately-held company is based in Oxford. Evolito’s investors include Waypoint Capital and Oxford Science Enterprises (OSE).
YASA http://www.yasa.com/
YASA, part of Mercedes-Benz AG, is a pioneer in next-generation electric drive technology. YASA’s unique axial-flux electric motor technology offers the greatest efficiencies and highest power densities in class for the smallest size and weight. YASA is based in Oxford and Welshpool, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom